Fastman, J.
Foss-Feig, J. http://orcid.org/0000-0002-1491-8248
Frank, Y. http://orcid.org/0000-0003-0979-1032
Halpern, D. http://orcid.org/0000-0001-6745-1197
Harony-Nicolas, H. http://orcid.org/0000-0001-8283-9093
Layton, C.
Sandin, S. http://orcid.org/0000-0001-6994-4884
Siper, P. http://orcid.org/0000-0002-9659-8232
Tang, L.
Trelles, P. http://orcid.org/0000-0002-7442-3677
Zweifach, J. http://orcid.org/0000-0001-5392-8839
Buxbaum, J. D. http://orcid.org/0000-0001-8898-8313
Kolevzon, A. http://orcid.org/0000-0001-8129-2671
Funding for this research was provided by:
Beatrice and Samuel A. Seaver Foundation
Article History
Received: 22 February 2021
Accepted: 19 July 2021
First Online: 30 September 2021
Declarations
:
: The protocol was approved by the Mount Sinai Program for the Protection of Human Subjects and all caregivers signed informed consent.
: Not applicable.
: AK receives research support from AMO Pharma and consults to Acadia, Alkermes, and Ovid Therapeutics. JDB has a shared patent with Mount Sinai for IGF-1 in Phelan-McDermid syndrome. No other authors have competing interests to disclose.